Who
Kabeer Aziz
Director
Company insider
Files Form 4 as: Director and 10% owner, AN2 Therapeutics.
In numbers
- Trades disclosed
- 56
- Buys
- 1
- Sells
- 10
- Bought
- $2.5M
- Sold
- $4.0M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 29 Mar 2022
- Last trade
- 12 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 13 Oct 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,465 at $0.00 | filing |
| 10 Jul 2026filed 10 Jul 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,852 at $0.00 | filing |
| 10 Jul 2026filed 10 Jul 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,852 at $0.00 | filing |
| 10 Apr 2026filed 10 Apr 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,775 at $0.00 | filing |
| 10 Apr 2026filed 10 Apr 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,775 at $0.00 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,724 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,724 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,724 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,724 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,742 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —11,560 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —11,560 at $0.00 | filing |
| 10 Oct 2025filed 14 Oct 2025 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,367 at $0.00 | filing |
| 10 Jul 2025filed 11 Jul 2025 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —11,875 at $0.00 | filing |
| 22 May 2025filed 23 May 2025 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,111 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.